Cann Group Ltd. · ASX:CAN
Cann — Shareholder Meeting (November 2019)
25 slides from Cann's shareholder meeting presentation, Nov 29, 2019
Slide 1: Annual General Meeting
GROUP LIMITED Annual General Meeting 29 November 2019 1
Slide 2: Chairman's address
Chairman’s address Allan McCallum Refer to ASX Announcement lodged 29 November 2019 2
Slide 3: CEO's address
CEO’s address Peter Crock Refer to ASX Announcement lodged 29 November 2019 3
Slide 4: Fully integrated & globally competitive medicinal cannabis company
Fully integrated & globally competitive medicinal cannabis company • Cann is combining in-house capabilities with strategic partnerships to undertake – Industry-leading research & product development – Cost-efficient cultivation on a large scale – Manufacturing of GMP grade medicinal products – Sale
Slide 5: Key building blocks in place
Key building blocks in place • Cultivars – International genetics program has allowed Cann to test, identify & focus on strains with the most compelling attributes for cultivation at scale, including profiling strains required by Aurora • Licenses & Permits – Holds all required licences & permits fo
Slide 6: Large scale Mildura facility to be completed on staged basis
Large scale Mildura facility to be completed on staged basis • State-of-the-art facility, incorporating world-leading design/technology • Revised construction plan more closely aligns capacity with anticipated demand & lowers capital investment risk • Detailed design; scheduling; & cost now being de
Slide 7: Han
Han —b-——
Slide 8: SIN
\’ SIN So
Slide 9: amc
amc
Slide 10: Proven cultivation & production model
Proven cultivation & production model • Ongoing cultivation & harvest cycle utilising Southern & Northern facilities • 51 harvests completed including Aurora sourced cultivars • 24 imported varieties of medicinal cannabis currently being evaluated • First harvests of internationally sourced genetics
Slide 11: Experienced pharmaceutical partner with product validation underway
Experienced pharmaceutical partner with product validation underway • IDT Australia (ASX:IDT) for manufacturing support in relation to cannabis-based product formulations • IDT brings excellent capabilities & experience in the manufacture of cGMP quality pharmaceuticals • Partnership with IDT provid
Slide 12: Both local & imported products ready to launch
Both local & imported products ready to launch • Product development & validation on track for domestic launch of locally made Cann products by Q1 CY2020 • New imported product from Aurora received with first orders secured • Wholesale & distribution agreement with Symbion (4,000 pharmacies, 1,300 h
Slide 13: Regulatory approvals
Regulatory approvals • Manufacturing licences received for Cann’s Southern & Northern facilities • Cann holds all necessary cultivation, production & manufacturing licences in addition to import & export licences • May 2019 – IDT Australia granted manufacturing licence • June 2019 – Aurora receives
Slide 14: Strong relationship with Aurora Cannabis Inc
Strong relationship with Aurora Cannabis Inc • Offtake agreement secured with Aurora for Cann’s TGA/GMP quality product. Aurora has an established presence in 24 countries • Agronomic support & access to cultivation & manufacturing related IP • Technical Services Agreement between Cann & Aurora – pr
Slide 15: A growing domestic & export market
A growing domestic & export market Australian patient approvals continue momentum Export potential growing across worldwide Medicinal cannabis market size forecast SAS Category B approvals by month 4000 3500 3594 Region Market Value 2024 (US$b) 2887 2913 3000 Africa 1.3 2500 2207 Asia 10.7 2000 1566
Slide 16: Clinical trials involving cannabis – 2019
Clinical trials involving cannabis – 2019 Source: US National Library of Medicine/ Prohibition Partners 16
Slide 17: Financial statements and reports
ITEM 1 Financial statements and reports 17
Slide 18: Adoption of Remuneration Report
ITEM 2 Adoption of Remuneration Report For Proxy’s Against Abstain Discretion 38,243,153 2,556,257 900,103 176,576 18
Slide 19: Re-election of Director – Mr Allan McCallum
ITEM 3 Re-election of Director – Mr Allan McCallum For Proxy’s Against Abstain Discretion 44,985,890 2,234,764 76,971 158,464 19
Slide 20: Re-election of Director – Mr Douglas Rathbone
ITEM 4 Re-election of Director – Mr Douglas Rathbone For Proxy’s Against Abstain Discretion 44,983,086 2,234,263 81,125 157,615 20
Slide 21: Ratification of prior issue of shares
ITEM 5 Ratification of prior issue of shares For Proxy’s Against Abstain Discretion 44,237,776 2,555,484 521,761 141,068 21
Slide 22: Ratification of prior issue of shares
ITEM 6 Ratification of prior issue of shares For Proxy’s Against Abstain Discretion 43,912,437 2,717,816 517,348 149,786 22
Slide 23: Approval of long-term incentive plan
ITEM 7 Approval of long-term incentive plan For Proxy’s Against Abstain Discretion 38,304,817 2,390,207 887,606 134,757 23
Slide 24: Approval of 10% placement capacity for 12 months
ITEM 8 Approval of 10% placement capacity for 12 months For Proxy’s Against Abstain Discretion 43,730,163 2,404,488 1,172,905 148,533 24
Slide 25: Contacts
GROUP LIMITED CONTACTS: Clive Fanning Head of Investor Relations Cann Group Limited +61 (0)498 000 762 contact@canngrouplimited.com Matthew Wright Investor / Media Relations NWR Communications +61 (0)451 896 420 matt@nwrcommunications.com.au 25